Abstracts tagged "psoriasis and rheumatoid arthritis (RA)"

Abstract Number: 906 • 2015 ACR/ARHP Annual Meeting
Distinct Expression of IL-36Î±, β, Î³ and Their Antagonists IL-36Ra and IL-38 in Psoriasis, Rheumatoid Arthritis and Crohn’s Disease
Marie-Astrid Boutet¹, Géraldine Bart², Jérôme Amiaud¹, Bénédicte Brulin³, Céline Charrier³, Franck Morel⁴, Jean-Claude Lecron⁴, Malvyne Rolli-Derkinderen⁵, Arnaud Boureille⁶, Cem Gabay⁷, Gaby Palmer⁸, Benoit Le Goff² and Frédéric Blanchard⁹, ¹Laboratoire de physiologie de la résorption osseuse, Inserm UMR 957, Nantes, France, ²Rheumatology, Nantes University Hospital, Nantes, France, ³Inserm UMR 957, Nantes, France, ⁴EA 4331, Poitiers, France, ⁵Inserm UMR 913, Nantes, France, ⁶Hepato-Gastroenterology Unit, Nantes University Hospital, Nantes, France, ⁷Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁸Geneva University Hospital, Geneva, Switzerland, ⁹Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Inserm UMR 957, Nantes, France
Background/Purpose: The IL-36 family of cytokines comprises three agonists, IL-36α, IL-36β and IL-36g, an antagonist IL-36Ra, as well as IL-38, another potential IL-36 inhibitor. IL-36…
Abstract Number: 1505 • 2014 ACR/ARHP Annual Meeting
The Biosimilar Landscape: A Systematic Review of Its Current Status
Niti Goel^1,2 and Kamali Chance³, ¹Rheumatology Center of Excellence, Quintiles, Durham, NC, ²Duke University Medical Center, Durham, NC, ³Global Biosimilars Unit, Quintiles, Durham, NC
Background/Purpose In the last 5 years, the number of biosimilars in development for the treatment of immunologic diseases has increased as innovator etanercept (ETA), infliximab (IFX), adalimumab…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].